Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Convertible Preferred Stock Pfizer License Agreement	Initial Public Offering	Common Stock	Common Stock Initial Public Offering	Additional paid-in capital	Additional paid-in capital Initial Public Offering	Accumulated deficit
Beginning balance at Dec. 31, 2019		$ 21,942
Beginning Balance, Shares at Dec. 31, 2019		22,724,925
Beginning balance at Dec. 31, 2019	$ (2,874)				$ 1		$ 40		$ (2,915)
Beginning Balance, Shares at Dec. 31, 2019					828,356
Issuance of common stock	3						3
Issuance of common stock (Shares)					49,061
Vesting of restricted common stock	10						10
Vesting of restricted common stock (Shares)					411,925
Stock-based compensation	44						44
Net loss	(12,828)								(12,828)
Ending balance at Dec. 31, 2020		$ 21,942
Ending balance (in shares) at Dec. 31, 2020		22,724,925
Ending balance at Dec. 31, 2020	(15,645)				$ 1		97		(15,743)
Ending balance (in shares) at Dec. 31, 2020					1,289,342
Issuance of Series B convertible preferred stock		$ 152,081	$ 20,000
Issuance of Series B convertible preferred stock, Shares		92,660,103	12,152,145
Issuance of common stock				$ 152,296		$ 11		$ 152,285
Issuance of common stock (Shares)						10,500,000
Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock		$ (194,023)
Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)		(127,537,173)
Conversion of Series A and Series B convertible preferred stock into shares of common stock	194,023				$ 20		194,003
Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)					20,056,145
Stock options exercised	$ 170						170
Stock options exercised (Shares)	70,396				70,396
Vesting of restricted common stock	$ 3						3
Vesting of restricted common stock (Shares)					306,998
Stock-based compensation	6,441						6,441
Net loss	(75,975)								(75,975)
Ending balance (in shares) at Dec. 31, 2021		0
Ending balance at Dec. 31, 2021	$ 261,313				$ 32		$ 352,999		$ (91,718)
Ending balance (in shares) at Dec. 31, 2021					32,222,881